AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ABIVAX

Report Publication Announcement Jan 25, 2022

1063_rns_2022-01-25_d13b32dd-a267-4fd2-b923-3d2453af4d08.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

News Details

Corporate | 25 January 2022 18:00

Abivax 2022 Financial Communication Calendar

DGAP-News: ABIVAX / Key word(s): Miscellaneous

25.01.2022 / 18:00

The issuer is solely responsible for the content of this announcement.

Abivax 2022 Financial Communication Calendar

PARIS, France, January 25, 2022 – 6:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases and cancer, today publishes its 2022 financial communication calendar.

  • Wednesday, March 16, 2022

    Publication of financial statements as of December 31, 2021

  • Friday, April 15, 2022

    Publication and release of the 2021 annual financial report

  • Monday, May 23, 2022 – 10.00 a.m. (CEST)

    Shareholders’ meeting

  • Thursday, September 15, 2022

    Publication of financial statements as of June 30, 2022

  • Friday, September 30, 2022

    Publication and release of 2022 half year report

*****

About Abivax (www.abivax.com)

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.

Contact s

Abivax

Communications

Regina Jehle

[email protected]

+33 6 24 50 69 63
Investors

LifeSci Advisors

Ligia Vela-Reid

[email protected]

+44 7413 825310
Press Relations & Investors Europe

MC Services AG

Anne Hennecke

[email protected]

+49 211 529 252 22
Public Relations France

Actifin

Ghislaine Gasparetto

[email protected]

+33 6 21 10 49 24
Public Relations France

DGM Conseil

Thomas Roborel de Climens

[email protected]

+33 6 14 50 15 84
Public Relations USA

Rooney Partners LLC

Jeanene Timberlake

[email protected]

+1 646 770 8858

25.01.2022 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.